Omeros Corp (OMER)

11.56
0.04 0.35
NASDAQ : Health Care
Prev Close 11.52
Open 11.50
Day Low/High 11.37 / 11.59
52 Wk Low/High 8.90 / 30.23
Volume 137.89K
Avg Volume 350.00K
Exchange NASDAQ
Shares Outstanding 39.29M
Market Cap 447.94M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy In Paroxysmal Nocturnal Hemoglobinuria Model

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy In Paroxysmal Nocturnal Hemoglobinuria Model

Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program.

Omeros Corporation Reports Second Quarter 2016 Financial Results

Omeros Corporation Reports Second Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce Second Quarter 2016 Financial Results On August 9, 2016

Omeros Corporation To Announce Second Quarter 2016 Financial Results On August 9, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade Of The Alternative Pathway Of Complement System

Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade Of The Alternative Pathway Of Complement System

Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program.

Omeros Corporation Confirms OMS721 Phase 3 Development Plan With European Medicines Agency

Omeros Corporation Confirms OMS721 Phase 3 Development Plan With European Medicines Agency

-- One Single-Arm, Open-Label Phase 3 Pivotal Trial Planned to Support Approval in Both Europe and the U.S. --

Omeros To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference

Omeros To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference

Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Commit To Buy Omeros Corp At $10, Earn 26.6% Annualized Using Options

Commit To Buy Omeros Corp At $10, Earn 26.6% Annualized Using Options

Investors eyeing a purchase of Omeros Corp stock, but cautious about paying the going market price of $11.42/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $10 strike, which has a bid at the time of this writing of $1.65.

Omeros Corporation Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA®

Omeros Corporation Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA®

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros (OMER) Is Today's Strong On High Volume Stock

Omeros (OMER) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Omeros (OMER) as a strong on high relative volume candidate

Omeros Announces Debt Financing Transaction For $20 Million In Additional Funds

Omeros Announces Debt Financing Transaction For $20 Million In Additional Funds

Omeros Corporation (NASDAQ: OMER) (the "Company") today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford") and East West Bank ("East West") to provide the...

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

Omeros Corporation Reports First Quarter 2016 Financial Results

Omeros Corporation Reports First Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Leonard M. Blum Joins Omeros To Lead Business And Commercial Activities

Leonard M. Blum Joins Omeros To Lead Business And Commercial Activities

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Announces Exclusive Middle East Distribution Agreement For OMIDRIA®

Omeros Corporation Announces Exclusive Middle East Distribution Agreement For OMIDRIA®

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Becomes Oversold (OMER)

Omeros Becomes Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Omeros Corporation To Announce First Quarter 2016 Financial Results On May 10, 2016

Omeros Corporation To Announce First Quarter 2016 Financial Results On May 10, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Announces Independent Studies With OMIDRIA® To Be Presented At Upcoming Ophthalmology Congresses

Omeros Corporation Announces Independent Studies With OMIDRIA® To Be Presented At Upcoming Ophthalmology Congresses

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases

Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases

Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases.

Commit To Purchase Omeros Corp At $10, Earn 13.8% Annualized Using Options

Commit To Purchase Omeros Corp At $10, Earn 13.8% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but tentative about paying the going market price of $16.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $10 strike, which has a bid at the time of this writing of 85 cents.

Omeros To Present At The 15th Annual Needham Healthcare Conference

Omeros To Present At The 15th Annual Needham Healthcare Conference

Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros (OMER) Is Today's Strong On High Volume Stock

Omeros (OMER) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Omeros (OMER) as a strong on high relative volume candidate

Omeros Corporation Initiates Its Phase 3 Program For OMS721 In AHUS Following Meeting With FDA

Omeros Corporation Initiates Its Phase 3 Program For OMS721 In AHUS Following Meeting With FDA

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Reports Fourth Quarter And Year-End 2015 Financial Results

Omeros Corporation Reports Fourth Quarter And Year-End 2015 Financial Results

Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros To Present At The Cowen And Company 36th Annual Health Care Conference

Omeros To Present At The Cowen And Company 36th Annual Health Care Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce Fourth Quarter And Year-End 2015 Financial Results On March 8, 2016

Omeros Corporation To Announce Fourth Quarter And Year-End 2015 Financial Results On March 8, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Physicians Increasingly Seek Access To OMS721 Compassionate Use Program

Physicians Increasingly Seek Access To OMS721 Compassionate Use Program

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...